Wexford Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Wexford Capital’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,000	Closed	-$14K	–	279
2020 Q4	$14K	Buy	+4,000	New	+$7.63K	﹤0.01%	301

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wexford Capital's LXRX Position: Q1 2021 in Review

Wexford Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2021, closing a stake of 4,000 shares — an estimated $14K sold.

Wexford Capital first reported a position in LXRX in Q4 2020 and held it in 1 quarter. The position peaked at $14K in Q4 2020. 107 funds tracked by Wall St. Rank hold LXRX as of Q1 2021.

Wexford Capital reported no remaining Lexicon Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Wexford Capital sold 4,000 Lexicon Pharmaceuticals shares in Q1 2021, an estimated $14K.
Wexford Capital first reported a position in Lexicon Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Wexford Capital's Lexicon Pharmaceuticals position peaked at $14K in Q4 2020.
107 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.